Taxus Cardium Pharm Group Inc (fka CRXM)

[califax]

Cardium to Present at MDB Capital Group's 2010 Bright Lights Conference

07.05.2010 15:05
http://www.finanznachrichten.de/nachrichten-2010-05/16842707-cardium-to-present-at-mdb-capital-group-s-2010-bright-lights-conference-008.htm

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) has been invited to present at the 2010 MDB Capital Group's Bright Lights Conference. The conference will be held May 10-12, 2010 at the Palace Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Cardium's Chairman and Chief Executive Officer, Christopher J. Reinhard is presenting on Tuesday, May 11, 2010 and a copy of the presentation is available at the Investors section of Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

The inaugural Bright Lights Conference will showcase 50 of the most innovative public companies ranked in the 90th percentile for technology leadership. The presenters were chosen from over 1,600 small cap companies with U.S. patents, as rated by PatentVest, MDB Capital Group's proprietary IP business intelligence database. The conference will include company presentations, expert panels, IP workshops and one-on-one investor meetings. Additionally, MDB Capital Group will provide analysis and objective data regarding the technology leadership and competitive landscape of the companies presenting during this exclusive, invitation-only event. For more information about the conference, visit http://www.mdb.com/bright-lights-conference.html.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at http://www.cardiumthx.com/.

Copyright 2010 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com/.

Cardium Therapeutics(TM) and Generx® and MedPodium(TM) are trademarks of Cardium Therapeutics, Inc.

Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM), Excellagen(TM), Excellarate(TM) and Osteorate(TM) are trademarks of Tissue Repair Company.
Photo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO
http://photoarchive.ap.org/
PRN Photo Desk, [e-mail]

Cardium Therapeutics

CONTACT: Bonnie Ortega, Director, Investor/Public Relations of Cardium
Therapeutics, Inc., [phone], [e-mail]

Web Site: http://www.cardiumthx.com/


© 2010 PR Newswire